Back to top
more

Inspire Medical Systems (INSP)

(Delayed Data from NYSE)

$126.10 USD

126.10
907,460

+1.56 (1.25%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $126.01 -0.09 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (63 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Butterfly Network, Inc. (BFLY) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Butterfly Network (BFLY) delivered earnings and revenue surprises of +14.29% and -2.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Doximity (DOCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?

by Zacks Equity Research

Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.

Zacks Equity Research

Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition

by Zacks Equity Research

TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.

Zacks Equity Research

Here's Why You Should Retain AMED Stock in Your Portfolio for Now

by Zacks Equity Research

Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.

Zacks Equity Research

Is the Options Market Predicting a Spike in Inspire Medical Systems Stock?

by Zacks Equity Research

Investors need to pay close attention to INSP stock based on the movements in the options market lately.

Zacks Equity Research

Here's Why You Should Retain PODD Stock in Your Portfolio Now

by Zacks Equity Research

Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.

Zacks Equity Research

Is it Apt to Retain Omnicell Stock in Your Portfolio Now?

by Zacks Equity Research

OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.

Zacks Equity Research

Inspire (INSP) Down 14.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain ICLR Stock in Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.

Zacks Equity Research

Is Bio-Techne Stock the Right Pick for Your Portfolio Now?

by Zacks Equity Research

TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today?

Zacks Equity Research

Prestige Consumer Gains 35.7% in a Year: What's Driving the Stock?

by Zacks Equity Research

PBH stock jumps on the back of brand strength, e-commerce gains and smart acquisitions despite tariff and foreign exchange headwinds.

Zacks Equity Research

Insulet Gains 78.5% in a Year: What's Driving the Stock?

by Zacks Equity Research

PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.

Zacks Equity Research

Should You Retain Henry Schein Stock in Your Portfolio Right Now?

by Zacks Equity Research

Investors are optimistic about HSIC, owing to the strong performance of its Henry Schein One business.

Zacks Equity Research

Penumbra Rallies 35.9% in a Year: What's Driving the Stock?

by Zacks Equity Research

PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.

Zacks Equity Research

Should Tandem Diabetes Stock Stay in Your Portfolio Now?

by Zacks Equity Research

Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.

Zacks Equity Research

What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?

by Zacks Equity Research

DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.

Zacks Equity Research

Should You Continue to Hold Charles River Stock in Your Portfolio?

by Zacks Equity Research

CRL stays on investors' radars due to the strength of partnerships and segmental prospects.

Zacks Equity Research

Omnicell's New Perioperative Clinic Setting Products May Boost Stock

by Zacks Equity Research

OMCL unveils new offerings for the perioperative and clinic setting.

Zacks Equity Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

All You Need to Know About Inspire (INSP) Rating Upgrade to Buy

by Zacks Equity Research

Inspire (INSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).